Advances in the Study of PDE4 Inhibitors in Dermatological Disorders

Wei Jiang; Xueyong Wang; Shan Li; Nan Li; Zhongwei Li; Zhiguo Xu

doi:10.54097/a1y90g60

Authors

Wei Jiang
Xueyong Wang
Shan Li
Nan Li
Zhongwei Li
Zhiguo Xu

DOI:

https://doi.org/10.54097/a1y90g60

Keywords:

Phosphodiesterase 4 inhibitor; dermatological disorders; cAMP-PKA signaling pathway; apremilast; crisaborole.

Abstract

Since the 1980s, phosphodiesterase 4 (PDE-4) has been one of the most prominent targets for the treatment of inflammatory diseases. More recently, a number of synthetic ligands targeting PDE-4 have received more attention in the academic and pharmaceutical communities and are expected to have applications in these diseases. Due to various potential side effects of PDE-4 inhibitors, there are several obstacles to the clinical translation of specific PDE-4 inhibitors from the preclinical to the clinical phase. Therefore, similar to roflumilast in chronic obstructive pulmonary disease, many PDE-4 inhibitors can take up to 30 years or even longer from development to clinical application. This article is a review of the development of PDE-4 inhibitors, such as crisaborole and apremilast, for use in skin disorders.

Downloads

Download data is not yet available.

References

Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109(3):366-398.

De Souza A, Strober BE, Merola JF, Oliver S, Franks AG, Jr. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study. J Drugs Dermatol. 2012;11(10):1224-1226.

Eskandari N, Mirmosayyeb O, Bordbari G, Bastan R, Yousefi Z, Andalib A. A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool. J Res Pharm Pract. 2015;4(4):175-181.

Sakkas LI, Mavropoulos A, Bogdanos DP. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives. Curr Med Chem. 2017;24(28):3054-3067.

Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2017;12(12):CD011535.

Li H, Zuo J, Tang W. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Front Pharmacol. 2018;9:1048.

Mehta H, Sharma A, Dogra S. Evolving utility of apremilast in dermatological disorders for off-label indications. Clin Exp Dermatol. 2022;47(12):2136-2149.

Crocetti L, Floresta G, Cilibrizzi A, Giovannoni MP. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. Molecules. 2022;27(15).

Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: A review of literature. Dermatol Ther. 2020;33(6):e14261.

Peng T, Gong J, Jin Y, et al. Inhibitors of phosphodiesterase as cancer therapeutics. Eur J Med Chem. 2018;150:742-756.

Cohen SR, Gordon SC, Lam AH, Rosmarin D. Recalcitrant Seborrheic Dermatitis Successfully Treated With Apremilast. J Cutan Med Surg. 2020;24(1):90-91.

Elhage KG, Zhao R, Nakamura M. Advancements in the Treatment of Cutaneous Lupus Erythematosus and Dermatomyositis: A Review of the Literature. Clin Cosmet Investig Dermatol. 2022;15:1815-1831.

Alharthy RF, Alharthy JM, Bawazir RO, Katib RI, Alharthy FS. The Efficacy and Safety of Apremilast in the Management of Psoriatic Arthritis: A Systematic Review and Meta-Analysis. Cureus. 2024;16(3):e55773.

Li H, Zhang Z, Zhang H, Guo Y, Yao Z. Update on the Pathogenesis and Therapy of Atopic Dermatitis. Clin Rev Allergy Immunol. 2021;61(3):324-338.

Chu DK, Chu AWL, Rayner DG, et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152(6):1493-1519.

Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):e1-e20.

Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486.

Hong JJ, Mosca ML, Hadeler EK, Brownstone ND, Bhutani T, Liao WJ. Genital and Inverse/Intertriginous Psoriasis: An Updated Review of Therapies and Recommendations for Practical Management. Dermatol Ther (Heidelb). 2021;11(3):833-844.

Leung YY, Korotaeva TV, Candia L, et al. Management of Peripheral Arthritis in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol. 2023;50(1):119-130.

Xu Y, Li Z, Wu S, Guo L, Jiang X. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis. Front Immunol. 2023;14:1180170.

Ezzedine K, Vance TM, Hamzavi IH, Qureshi AA. Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology. J Invest Dermatol. 2020;140(8):1498-1500.

Perez-Bootello J, Cova-Martin R, Naharro-Rodriguez J, Segurado-Miravalles G. Vitiligo: Pathogenesis and New and Emerging Treatments. Int J Mol Sci. 2023;24(24).

Sharma S, Bhardwaj A, Dwivedi P, et al. Apremilast Add-On Benefits Over Conventional Drugs (ABCD) in Unstable Non-segmental Vitiligo: A 12-Week Single-Center Randomized Controlled Trial. Cureus. 2023;15(4):e37180.

Jafarzadeh A, Pour Mohammad A, Khosravi M, et al. A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo. Skin Res Technol. 2024;30(3):e13642.

Saisorn W, Saithong S, Phuengmaung P, et al. Acute Kidney Injury Induced Lupus Exacerbation Through the Enhanced Neutrophil Extracellular Traps (and Apoptosis) in Fcgr2b Deficient Lupus Mice With Renal Ischemia Reperfusion Injury. Front Immunol. 2021;12:669162.

Jackson JM, Alexis A, Zirwas M, Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2024;90(3):597-604.